Al-Sawaf O et al. Clonal dynamics after venetoclax-obinutuzumab therapy: Novel insights from the randomized, phase 3 CLL14 trial. ASH 2020;Abstract 127.

Byrd JC et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol 2021;[Online ahead of print]. Abstract

Hillmen P et al. First interim analysis of ALPINE study: Results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2021;Abstract LB1900.

Kater A et al. Fixed-duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (CLB+O) for first-line (1L) chronic lymphocytic leukemia (CLL): Primary analysis of the phase 3 GLOW study. EHA 2021;Abstract LB1902.

Mato AR et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study. Lancet 2021;397(10277):892-901. Abstract

Phillips TJ et al. The combination of venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability. ASCO 2021;Abstract 7505.

Rule S et al. Long-term outcomes with ibrutinib versus the prior regimen: A pooled analysis in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with up to 7.5 years of extended follow-up. ASH 2019;Abstract 1538.

Tam CS et al. Ibrutinib plus venetoclax in patients with relapsed/refractory mantle cell lymphoma: Results from the safety run-in period of the phase 3 SYMPATICO study. ASH 2020;Abstract 2938.

Wang M et al. Acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma: Long-term efficacy and safety results from a phase 2 study. ASH 2020;Abstract 2040.